HealthEquity (HQY) EVP granted 17,582 restricted stock units, now holds 65,633 shares

Rhea-AI Filing Summary

Fiore Michael Henry reported acquisition or exercise transactions in this Form 4 filing.

HealthEquity, Inc. executive Michael Henry Fiore, EVP and Chief Commercial Officer, received a grant of 17,582 shares of common stock in the form of restricted stock units. Following this award, he directly holds 65,633 shares. The units vest 25% on April 1, 2027, then 6.25% each quarter for the next twelve quarters.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fiore Michael Henry

(Last) (First) (Middle)

C/O HEALTHEQUITY, INC.

15 W. SCENIC POINTE DR., STE. 100

(Street)

DRAPER UTAH 84020

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HEALTHEQUITY, INC. [ HQY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF COMMERCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/25/2026		A		17,582(1)	A	$0	65,633	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Shares vest as to 25% of the initial award on April 1, 2027. Shares shall vest as to 6.25% thereafter on the first day of each calendar quarter for the twelve calendar quarters following April 1, 2027.

	/s/ Michael Fiore	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did HealthEquity (HQY) report for Michael Henry Fiore?

HealthEquity reported that EVP and Chief Commercial Officer Michael Henry Fiore received a grant of 17,582 restricted stock units of common stock. This is a compensation-related award, not an open‑market purchase or sale, and increases his directly held position to 65,633 shares.

How many HealthEquity (HQY) shares does Michael Henry Fiore hold after this Form 4?

After the restricted stock unit grant, Michael Henry Fiore directly holds 65,633 shares of HealthEquity common stock. This total reflects the newly awarded 17,582 units, which convert into shares as they vest over the specified multi‑year schedule starting in April 2027.

What are the vesting terms of Michael Henry Fiore’s restricted stock units at HealthEquity (HQY)?

Each restricted stock unit represents one share of common stock. Twenty‑five percent of the initial 17,582‑unit award vests on April 1, 2027, and 6.25% vests on the first day of each calendar quarter for the twelve quarters that follow that initial vesting date.

Does the HealthEquity (HQY) Form 4 show an insider buy or sale of shares?

The Form 4 does not show an open‑market buy or sale. It reports an acquisition coded as a grant or award of 17,582 restricted stock units to executive Michael Henry Fiore, a standard equity compensation event rather than a discretionary market transaction.

What role does Michael Henry Fiore hold at HealthEquity (HQY) in this Form 4 filing?

In this filing, Michael Henry Fiore is identified as an officer of HealthEquity serving as Executive Vice President and Chief Commercial Officer. The reported transaction reflects equity compensation associated with this leadership role rather than personal trading activity in the open market.